Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24275794 | 0.82 | RXRA (0.36) | MAPK1 | |
| SCHEMBL31394278 | 0.77 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL12374406 | 0.74 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL6027768 | 0.72 | RXRA (0.35) | MAPK1 | |
| SCHEMBL26622502 | 0.72 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL30573018 | 0.71 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL26607091 | 0.71 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL13785154 | 0.70 | MAPK1 (0.37) | MAPK1 | |
| SCHEMBL547004 | 0.70 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL6027714 | 0.70 | RXRA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643993-A2 | SUBSTITUTED ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | disclosed |
| WO-2004093809-A2 | SUBSTITUTED ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | HSD17B10, IDH2, INSR | MAPK1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.